separately since its efficacy/safety profile is much different from that of other OSMs listed above. OSM-and other treatment-naive is defined as naive to treatment with OSMs, tumor necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i), and IL-12/23i; patients may have received nonsteroidal antiinflammatory drugs, glucocorticoids, and/or other pharmacologic and nonpharmacologic interventions. ยง Because there are currently no widely agreed-upon definitions of disease severity, PsA